BioWorld

May 12, 2009

NovImmune Raises $56.5M to Broaden Antibody Pipeline

NovImmune SA secured CHF62.5 million (US$56.5 million) in what may well turn out to be the largest private equity deal completed by a European biotechnology firm this year. (BioWorld Today) Read More

Biotech's Birthplace Fights to Preserve Innovation, Education

New Target For Inflammatory Aspects of Heart Disease

Health Groups Form Pact to Cut Costs by $2 Trillion

Ardea Restructures to Focus on its Clinical Programs

After Stock Bump, Hemispherx Bringing in $18.3M Publicly

Roche Partners with Tekmira to Advance Two RNAi Products

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...